Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

Idorsia Aktie News

Aktie
WKN:  A2DTEB ISIN:  CH0363463438 US-Symbol:  IDRSF Branche:  Biotechnologie Land:  Schweiz
3,505 CHF
-0,205 CHF
-5,53%
3,8230 € 17:31:43 Uhr
Depot/Watchlist
Marktkapitalisierung *
858,56 Mio. €
Streubesitz
55,25%
KGV
-0,58
Dividende
32,59 €
Dividendenrendite
130,87%
Index-Zuordnung
-

Idorsia News

16.04.25 - GlobeNewswire
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond
Ad hoc announcement pursuant to Art. 53 LR
09.04.25 - GlobeNewswire
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed ...
09.04.25 - GlobeNewswire
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk ...
27.03.25 - GlobeNewswire
Idorsia publishes its Annual Report 2024
Ad hoc announcement pursuant to Art. 53 LR
17.03.25 - GlobeNewswire
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
Ad hoc announcement pursuant to Art. 53 LR
14.03.25 - GlobeNewswire
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-​related endpoints in a placebo-​controlled study in patients with ...
04.03.25 - GlobeNewswire
Idorsia announces financial results for 2024
Ad hoc announcement pursuant to Art. 53 LR
27.02.25 - GlobeNewswire
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET.
26.02.25 - GlobeNewswire
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
Ad hoc announcement pursuant to Art. 53 LR
26.02.25 - GlobeNewswire
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
Ad hoc announcement pursuant to Art. 53 LR
26.02.25 - GlobeNewswire
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
Ad hoc announcement pursuant to Art. 53 LR
25.02.25 - GlobeNewswire
Bondholders approve amended terms of the 2025 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
12.02.25 - GlobeNewswire
Idorsia publishes the resolutions for the upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR

Newssuche

Videos

newspaper
10:20 Uhr +9,48%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »